Here is the rundown on market activity for Kite Pharma, Inc. (NASDAQ:KITE). EVP, Business Development Helen Susan Kim sold 35,900 shares at a price of $61.54 on August 15th. That brings the EVP, Business Development’s holdings to $553,860 per an SEC filing yesterday. Roy Doumani, Director reported the sale of 14,000 shares. The shares were purchased at an average price of $58.06. Doumani now owns $1,617,842 of the stock per the Form 4 SEC filing.
Today Rizwana F. Sproule, VP Regulatory Affairs disclosed the sale of 9,567 shares of (KITE). The shares were sold on February 17th for an average price of $45.54. The VP Regulatory Affairs now owns $398,065 of the stock according to the SEC filing.
Here are some other firms who have updated their holdings. As of quarter end Royal Bank Of Canada had acquired a total of 3 shares growing its holdings by 0.6%. The value of the investment in (KITE) increased from $24,000 to $26,000 increasing 8.3% quarter to quarter. Ifp Advisors, Inc grew its stake by buying 400 shares an increase of 142.9% as of 06/30/2016. Ifp Advisors, Inc now controls 680 shares with a value of $34,000. The value of the position overall is up by 161.5%.
As of the end of the quarter Schwab Charles Investment Management Inc had bought 34,871 shares growing its position 29.9%. The value in dollars went from $7,183,000 to $7,572,000 a change of 5.4% quarter over quarter. Stifel Financial Corp reduced its position by shedding 5,660 shares a decrease of 97.4% from 03/31/2016 to 06/30/2016. Stifel Financial Corp owns 150 shares valued at $8,000. The total value of its holdings decreased 97.0%.
September 27 investment analysts at Barclays made no change to the stock rating of “Equal-weight” but raised the price target to $65.00 from $58.00. On August 30, 2016 BTIG Research added KITE to its research portfolio with an initial rating of “Neutral”.
Barclays issued its first research report on the stock setting a rating of “Equal-weight” and projecting a price target of $58.00. Equity analyst Raymond James initiated coverage on KITE with a rating of “Outperform”.
On March 1 Jefferies maintained a company rating of “Buy” and lowered the price expectation from $92.00 to $75.00. March 1 investment analysts at Stifel Nicolaus held the stock rating at “Buy” and lowered the price target to $63.00 from $98.00.
The company is now down since yesterday’s close of $60.04. Shares are trading at $56.46 a tad under $58.29, the 50 day moving average and barely above the 200 day moving average of $51.62. The 50 day moving average went down $-1.83 or -3.14% and the 200 day average went up $4.84 or +9.38%.
In the latest earnings report the EPS was $-3.73 and is projected to be $-5.82 for the current year with 49,596,000 shares now outstanding. Next quarter’s EPS is expected be $-1.98 and the next full year EPS is anticipated to be $-6.43.
Traders are feeling more bullish on Kite Pharma, Inc. recently if you put credence in the motion in short interest. The company recorded a fall in short interest from August 31, 2016 to September 15, 2016 of -0.05%. Short interest decreased from 6,458,295 to 6,130,314 over that timeframe. The days to cover decreased to 8.5 and the percentage of shorted shares was 0.12% on September 15.